Skip to main content
HINOVA PHARMACEUTICALS INC. logo

HINOVA PHARMACEUTICALS INC. — Investor Relations & Filings

Ticker · 688302 ISIN · CNE1000059F5 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2022-04-28 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688302

About HINOVA PHARMACEUTICALS INC.

https://www.hinovapharma.com/

Hinova Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of cancers and metabolic diseases. The company leverages its core technology platforms, including targeted protein degradation (PROTAC) and deuterium-based drug discovery, to develop a diverse pipeline of small molecule therapeutics. Its lead candidate, HC-1119 (deuterenzalutamide), is a next-generation androgen receptor antagonist currently in late-stage clinical development for metastatic castration-resistant prostate cancer. Other key programs include HP518, an orally bioavailable PROTAC degrader targeting the androgen receptor, and HP501, a selective URAT1 inhibitor designed for the treatment of hyperuricemia and gout. Hinova aims to address significant unmet medical needs through the development of high-quality, differentiated therapies for global markets.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于海创药业股份有限公司使用部分暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from CITIC Securities regarding the use of temporarily idle raised funds by Haichuang Pharmaceutical Co., Ltd. for cash management. It references regulatory guidelines and approvals related to the management and use of raised funds, including the amount, purpose, risk control measures, and internal decision procedures. The document is not an annual or interim financial report, nor is it an earnings release or a call transcript. It is not a proxy statement or voting result announcement. It is a formal verification and opinion report by the sponsor institution on the company's compliance and use of raised funds, which aligns with the category of Audit Report / Information (AR) as it involves audit verification and regulatory compliance review related to raised funds usage. The document length is 3282 characters, which is substantive and contains detailed content, not just an announcement or certification letter, so it is not RPA or RNS. Therefore, the best fitting classification is AR (Audit Report / Information). FY 2022
2022-04-28 Chinese
海创药业：2022年第一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2022 年第一季度报告' which translates to '2022 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2022. The report is unaudited as indicated. The content includes comprehensive financial statements and analysis for a period shorter than a full fiscal year, consistent with an Interim / Quarterly Report. There is no indication that this is merely an announcement or a certification, and the document length (10864 characters) supports it being a full report rather than a brief announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2022
2022-04-28 Chinese
海创药业：独立董事关于公司第一届董事会第二十二次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent opinion statement from the independent directors of the company regarding various board meeting agenda items, including profit distribution plans, related party transactions, cash management proposals, and remuneration plans for directors and senior management. It discusses compliance with laws, regulations, and company bylaws, and confirms that the proposals do not harm shareholders' interests. The document is not a full financial report, earnings release, or regulatory filing but rather a formal board/management related announcement expressing independent directors' opinions on board meeting matters. Therefore, it fits best under Board/Management Information (MANG). The document length is 2276 characters, which is relatively short and focused on board opinions rather than full reports or announcements of report publications.
2022-04-28 Chinese
第一届监事会第十二次会议决议公告
Regulatory Filings Classification · 95% confidence The document is a resolution announcement from the Supervisory Board of a company regarding various agenda items including approval of the 2021 Supervisory Board Work Report, 2021 Financial Final Report, 2022 Financial Budget Report, 2021 Profit Distribution Proposal, and the 2022 First Quarter Report. It also mentions that these reports and proposals will be submitted to the 2021 Annual General Meeting for approval. The document itself does not contain the full financial reports but rather the resolutions and approvals of these reports. It also references that the detailed reports are published on the stock exchange website. The document length is short (2209 characters) and it serves as an official announcement of meeting resolutions rather than the reports themselves. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement and meeting resolution notice, not as the full Annual Report (10-K) or Interim Report (IR).
2022-04-28 Chinese
募集资金管理制度
Regulatory Filings Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the management, storage, usage, and reporting of funds raised by the company. It references regulatory requirements from Chinese securities laws and stock exchange rules, and outlines internal controls and reporting obligations related to raised capital. The content is a detailed policy or procedural document rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a brief announcement or presentation. It is a regulatory compliance document related to capital management, fitting best under Regulatory Filings (RNS) as it does not match other more specific categories like Capital/Financing Update (CAP) which would focus on actual financing events or Annual Report (10-K) which would include full financials. The document length (8170 characters) and detailed procedural content confirm it is not a short announcement or certification but a formal regulatory filing of internal capital management rules.
2022-04-28 Chinese
海创药业：2021年度董事会审计委员会履职情况报告
Audit Report / Information Classification · 95% confidence The document is titled as the "2021年度董事会审计委员会履职情况报告" which translates to "2021 Annual Board Audit Committee Performance Report." It details the audit committee's activities, meetings, supervision of external and internal audits, review of financial reports, related party transactions, and internal control guidance for the year 2021. The content focuses on the audit committee's oversight and evaluation of audit work and internal controls rather than presenting full financial statements or a comprehensive annual report. The document length is 2981 characters, which is relatively short and focused on audit committee duties and opinions. This aligns with the category of Audit Report / Information (AR), which includes standalone audit reports and related audit committee information, excluding full annual reports. It is not an announcement or a certification letter, so it is not RNS or RPA. Therefore, the best classification is AR with high confidence. FY 2021
2022-04-28 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.